tradmap

KLRS Earnings Kalaris Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$52 -$26 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $82500 $165000 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$190M -$95M $0 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$35 -$18 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$60M -$30M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-28% 52% 133% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–21 of 21
Q2 20262026-06-30-0.942026-08-1110-Q
Q1 20262026-03-31-0.462026-05-1210-Q
FY 20252025-12-31-2.852026-03-1710-K
Q3 20252025-09-30-2.412025-11-1210-Q
Q2 20262025-06-30-1.892026-08-1110-Q
Q1 20262025-03-31-2.522026-05-1210-Q
FY 20252024-12-31-51.772026-03-1710-K
Q3 20252024-09-30-35.442025-11-1210-Q
Q2 20252024-06-30-6.872025-08-1310-Q
Q1 20252024-03-31-2.602025-05-1410-Q
FY 20242023-12-31-42.092025-03-0710-K
Q3 20242023-09-30-1.302024-11-1210-Q
Q2 20242023-06-30-0.922024-08-0910-Q
Q1 20242023-03-31-0.442024-05-1310-Q
FY 20232022-12-31-2.202024-03-1510-K
Q3 20232022-09-30-1.832023-11-0210-Q
Q2 20232022-06-30-1.382023-08-0310-Q
Q1 20232022-03-31-0.692023-05-0410-Q
FY 20222021-12-31-2.742023-02-1510-K
Q3 20222021-09-30-1.822022-11-0310-Q
Q2 20222021-06-30-1.102022-08-0410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.